Top Page
Innovent Biologics
(1801)
Innovent Biologics (1801) vs. iShares MSCI Hong Kong ETF (EWH)
Innovent Biologics Business Overview & Revenue Model
Innovent Biologics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.42B | 9.42B | 6.21B | 4.56B | 4.27B | 3.84B |
| Gross Profit | 8.72B | 7.91B | 4.40B | 3.63B | 3.70B | 3.46B |
| EBITDA | 660.90M | -480.28M | -660.68M | -1.75B | -2.37B | -704.74M |
| Net Income | 1.13B | -94.63M | -1.03B | -2.18B | -2.73B | -998.42M |
Balance Sheet | ||||||
| Total Assets | 23.59B | 21.60B | 20.63B | 17.59B | 16.24B | 11.83B |
| Cash, Cash Equivalents and Short-Term Investments | 9.54B | 7.88B | 10.97B | 9.17B | 9.02B | 8.12B |
| Total Debt | 3.38B | 2.83B | 3.62B | 3.23B | 2.50B | 1.21B |
| Total Liabilities | 9.17B | 8.48B | 8.10B | 6.86B | 5.91B | 3.06B |
| Stockholders Equity | 14.42B | 13.12B | 12.53B | 10.73B | 10.33B | 8.78B |
Cash Flow | ||||||
| Free Cash Flow | 1.24B | -418.39M | -1.24B | -3.30B | -3.87B | -1.08B |
| Operating Cash Flow | 1.50B | 1.29B | 147.81M | -1.92B | -2.02B | -307.69M |
| Investing Cash Flow | -611.72M | -1.17B | -998.66M | -1.44B | -2.70B | -5.18B |
| Financing Cash Flow | -345.82M | -606.63M | 2.59B | 2.89B | 5.00B | 4.91B |
Innovent Biologics Technical Analysis
Innovent Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $141.38B | 31.20 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | HK$34.13B | 38.35 | 27.37% | ― | 2.57% | 18.79% | |
55 Neutral | $148.82B | 116.92 | 8.41% | ― | 52.78% | ― | |
54 Neutral | $124.66B | 31.23 | 11.72% | 1.29% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$102.43B | -109.23 | -14.40% | ― | 33.46% | -7.60% | |
43 Neutral | HK$39.44B | -25.46 | -15.06% | ― | 39.02% | 48.26% |
Innovent Biologics Corporate Events
Innovent Biologics reported a 40% year-on-year increase in product revenue for the third quarter of 2025, reaching over RMB3.3 billion. This growth was driven by the expansion of its oncology and general biomedicine product portfolios, including the successful market uptake of products like mazdutide and SINTBILO. The approval of mazdutide for type 2 diabetes by China’s National Medical Products Administration further strengthens Innovent’s market position, aligning with its vision to become a global premier biopharmaceutical company.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$110.62 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics has entered a global strategic collaboration with Takeda Pharmaceuticals to accelerate the development of its next-generation cancer therapies, including late-stage investigational medicines IBI363 and IBI343, and an early-stage program IBI3001. This collaboration involves co-development and commercialization efforts, with Takeda taking the lead in the U.S. and holding exclusive rights outside of Greater China. Innovent will receive a $1.2 billion upfront payment, with potential milestones totaling up to $11.4 billion. This partnership is expected to enhance Innovent’s global market presence and offer significant financial benefits.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$96.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics has announced that its new drug, mazdutide, has received approval from China’s National Medical Products Administration for glycemic control in adults with type 2 diabetes. This approval marks mazdutide as the first dual glucagon/glucagon-like peptide-1 receptor agonist for this indication, offering comprehensive benefits such as glycemic control, weight reduction, and improvements in hepato-cardio-renal metabolic indicators. The approval is based on successful Phase 3 clinical trials demonstrating its efficacy and safety, positioning Innovent as a key player in addressing the diabetes epidemic in China, which has the largest population of type 2 diabetes patients in the world.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$100.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics announced the grant of 20,800 share options to five grantees, including Dr. Sherwin, an independent non-executive director, as part of its 2024 Share Scheme. This move aims to incentivize employees and directors, with options vesting over several years and tied to performance targets for non-executive employees. The grant reflects the company’s strategy to align employee and director interests with its long-term goals, potentially impacting its operational focus and stakeholder engagement.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$114.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. is a leading biopharmaceutical company based in China, specializing in the discovery, development, and commercialization of innovative medicines for cancer, cardiovascular, autoimmune, and eye diseases. The company is known for its robust pipeline of monoclonal antibodies, multi-specific antibodies, and other novel modalities.
Innovent Biologics announced a significant financial turnaround for the first half of 2025, with a 50.6% increase in revenue to RMB5,953.1 million, driven by strong performance in oncology products and expanded biomedicine offerings. The company reported a substantial improvement in profitability, with IFRS net profit reaching RMB834.3 million and Non-IFRS net profit at RMB1,213.2 million, highlighting operational efficiency and strategic execution.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics has announced the appointment of Dr. Stephen A. Sherwin as an independent non-executive director and a member of the strategy committee, effective August 26, 2025. Dr. Sherwin brings extensive experience in the life sciences and oncology sectors, which is expected to enhance Innovent’s strategic direction and strengthen its position in the biotechnology industry.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement underscores the company’s commitment to strong governance and strategic oversight, which may enhance its operational effectiveness and industry positioning.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics reported a significant increase in product revenue for the first half of 2025, exceeding RMB5.2 billion, driven by over 35% year-on-year growth. The second quarter alone saw revenue surpassing RMB2.7 billion, a 30% increase from the previous year, fueled by strong performance in both oncology and general biomedicine portfolios. Notably, the approval of mazdutide for weight management by China’s National Medical Products Administration marks a significant milestone in their general biomedicine segment. As the company continues to expand its product offerings and enhance its market presence, 2025 is seen as a pivotal year for Innovent Biologics as it advances towards its goal of becoming a leading global biopharmaceutical entity.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
Innovent Biologics, Inc. has announced that its Board of Directors will hold a meeting on August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, which could impact the company’s financial strategy and shareholder returns.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.